Game-changing cholesterol treatment requires just one injection instead of daily pills, showing up to 69% reduction in bad ...

An investigational drug called lerodalcibep lowered low-density lipoprotein (LDL) cholesterol, or “bad” cholesterol, by 50% or more, a new study showed. The year-long clinical trial included people ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with FDA approval for subcutaneous use. The LIBerate Program showed sustained ...

THURSDAY, Nov. 13, 2025 (HealthDay News) — A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections.

Patients unable to control their cholesterol levels with medications may someday be able to lower their "bad" cholesterol with a shot, according to research presented at the American Heart Association ...

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...

The first trial in humans of the precise gene-editing technique known as base editing has shown promising results for keeping cholesterol levels in check. The approach involves an injection of a ...

In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...